Author Archives : Editorial Team

Home  >>  Author : Editorial Team

VAXIMM Initiates Phase I/II Trial with VXM01 Oral T-cell Immunotherapy in Combination with PD-L1 Inhibitor Avelumab in Glioblastoma

On December 14, 2018, Posted by , In News, By , With Comments Off on VAXIMM Initiates Phase I/II Trial with VXM01 Oral T-cell Immunotherapy in Combination with PD-L1 Inhibitor Avelumab in Glioblastoma

VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the first patient has been dosed in a Phase I/II trial evaluating VXM01 oral immunotherapy in combination with avelumab*, a human anti-PD-L1 antibody, for the treatment of glioblastoma. The trial is part of a collaboration…

DKFZ/EMBL: Computer model to predict prostate cancer progress

On December 11, 2018, Posted by , In News, By , With Comments Off on DKFZ/EMBL: Computer model to predict prostate cancer progress

  IMAGE: Colourbox – Kiyoshi Takahase Segundo Cancer researchers have developed a computer model that can predict the course of disease for prostate cancer, based on cancer patient genomic and clinical data The model is currently being implemented at a prostate cancer clinic in Germany. The researchers have also found…

Baden-Württemberg awarded two research prizes to Heidelberg

On December 11, 2018, Posted by , In News, By , With Comments Off on Baden-Württemberg awarded two research prizes to Heidelberg

This year, the Landesforschungspreis Baden-Württemberg for excellence in applied research goes to Andreas Trumpp from the German Cancer Research Centre (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH). Theresia Bauer, Minister of Science, Research and the Arts, presented the 100,000 euro award at a…

Leibniz Prize for Hans-Reimer Rodewald (DKFZ)

On December 10, 2018, Posted by , In News, By , With Comments Off on Leibniz Prize for Hans-Reimer Rodewald (DKFZ)

Hans-Reimer Rodewald of the German Cancer Research Center receives the Gottfried Wilhelm Leibniz Prize 2019, the most important research award in Germany. Rodewald’s research revolves around the question of how the different types of immune cells develop from stem cells and together form a functional defence system. Hans-Reimer Rodewald ©…

Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors

On December 10, 2018, Posted by , In News, By , With Comments Off on Affimed Presents Data at ASH 2018 Substantiating Opportunity for AFM13 as Mono- and Combination Therapy in CD30-Positive Tumors

Data Confirm Clinical Single-Agent Activity of AFM13 in CD30-Positive Lymphoma with Cutaneous Presentation and Doubled Complete Response Rate of AFM13 in Combination with Keytruda® (Pembrolizumab) in Hodgkin Lymphoma Patients Future Combination Opportunities Include Combination of CD16A Immune Cell Engagers with Adoptive NK Cell Transfer Heidelberg, Germany, December 3, 2018 –…

DKFZ/EMBL: New Ways to Look at Protein-RNA Networks

On December 10, 2018, Posted by , In News, By , , With Comments Off on DKFZ/EMBL: New Ways to Look at Protein-RNA Networks

For their vital tasks, all RNA molecules in our cells require proteins as binding partners. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and colleagues from the European Molecular Biology Laboratory (EMBL) have developed the first method with which they can analyze the composition of the entire RNA-protein…

BioRN honorary membership for Prof. Stefan Meuer and Dr. Friedrich Richter

On December 6, 2018, Posted by , In Press Releases, With Comments Off on BioRN honorary membership for Prof. Stefan Meuer and Dr. Friedrich Richter

Heidelberg, 06.12.2018 BioRN 2018 Members’ assembly has been the occasion to award Prof. Stefan Meuer and Dr. Friedrich Richter with BioRN honorary membership for their long-lasting and outstanding contribution to the BioRN Network. Prof. S. Meuer and Dr. C. Tidona (Chair of BioRN Startegic Advisory Board) Dr. F. Richter and…

Solmic Research GmbH and the European Molecular Biology Laboratory enter into a research collaboration

On December 3, 2018, Posted by , In News, By , With Comments Off on Solmic Research GmbH and the European Molecular Biology Laboratory enter into a research collaboration

Solmic Research GmbH has entered into a research collaboration with the European Molecular Biology Laboratory (EMBL) with the goal to elucidate the mode of action of natural extracts. Natural extracts, such as active ingredients of plants, are the origin of medicine and are widely used for medical applications, especially in…

DKFZ/EMBL: Algorithm identifies multiple gene–environment relationships

On November 30, 2018, Posted by , In News, By , , With Comments Off on DKFZ/EMBL: Algorithm identifies multiple gene–environment relationships

Researchers at the German Cancer Research Center (DKFZ), EMBL’s European Bioinformatics Institute (EMBL-EBI) and the Wellcome Sanger Institute have developed a new computational method that makes it possible to identify the impact of hundreds of environmental factors on genotype–environment interactions. The method will enhance understanding of relationship between genotype and…

BioRN Lounge: Learning the physiological basis of the Cocktail Party effect with Eckhard Friauf from TU Kaiserslautern.

On November 28, 2018, Posted by , In Press Releases, By , With Comments Off on BioRN Lounge: Learning the physiological basis of the Cocktail Party effect with Eckhard Friauf from TU Kaiserslautern.

Heidelberg, 28.11.2018 Last BioRN Lounge of the year before the winter sleep, led us to the magical world of hearing.   As usual it was the occasion for life science companies as well for scientists from our research institutes, to meet and chat about latest news and achievements. The BioRN…